细胞疗法对成骨不全症的潜在影响。
Potential implications of cell therapy for osteogenesis imperfecta.
作者信息
Niyibizi Christopher, Li Feng
出版信息
Int J Clin Rheumtol. 2009 Feb 1;4(1):57-66. doi: 10.2217/17584272.4.1.57.
Abstract
Osteogenesis imperfecta (OI) is a brittle-bone disease whose hallmark is bone fragility. Since the disease is genetic, there is currently no available cure. Several pharmacological agents have been tried with not much success, except the recent use of bisphosphonates. Stem cells have been suggested as an alternative OI treatment, but many hurdles remain before this technology can be applied for treating patients with OI. This review summarizes what is known at present regarding the application of stem cells to treat OI using animal models, clinical trials using mesenchymal stem cells to treat patients with OI and the knowledge gained from the clinical trials. Application of gene therapy in combination with stem cells is also discussed. The hurdles to be overcome to bring stem cells close to the clinic and future perspectives are discussed.
摘要
成骨不全症（OI）是一种以骨骼脆弱为特征的脆骨病。由于该疾病是遗传性的，目前尚无可用的治愈方法。除了最近使用双膦酸盐外，已经尝试了几种药物，但效果不太理想。干细胞已被提议作为一种治疗OI的替代方法，但在该技术可应用于治疗OI患者之前，仍有许多障碍。本综述总结了目前关于使用动物模型将干细胞应用于治疗OI、使用间充质干细胞治疗OI患者的临床试验以及从临床试验中获得的知识。还讨论了基因治疗与干细胞联合应用的情况。讨论了使干细胞接近临床所需克服的障碍以及未来前景。
相似文献
1
Potential implications of cell therapy for osteogenesis imperfecta.细胞疗法对成骨不全症的潜在影响。
Int J Clin Rheumtol. 2009 Feb 1;4(1):57-66. doi: 10.2217/17584272.4.1.57.
2
Current and Developing Pharmacologic Agents for Improving Skeletal Health in Adults with Osteogenesis Imperfecta.用于改善成骨不全成人骨骼健康的现有及正在研发的药物制剂
Calcif Tissue Int. 2024 Dec;115(6):805-811. doi: 10.1007/s00223-024-01188-2. Epub 2024 Mar 12.
3
Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.患者处理：成骨不全症成人骨折风险降低的药物治疗方法。
J Clin Endocrinol Metab. 2023 Jun 16;108(7):1787-1796. doi: 10.1210/clinem/dgad035.
4
[Osteogenesis imperfecta and achievements in cell and gene therapy].[成骨不全症与细胞和基因治疗的进展]
Acta Med Croatica. 2010 Jul;64(3):191-200.
5
Animal models of osteogenesis imperfecta: applications in clinical research.成骨不全症的动物模型：在临床研究中的应用
Orthop Res Rev. 2016 Sep 27;8:41-55. doi: 10.2147/ORR.S85198. eCollection 2016.
6
Current Overview of Osteogenesis Imperfecta.成骨不全症概述。
Medicina (Kaunas). 2021 May 10;57(5):464. doi: 10.3390/medicina57050464.
7
The synergistic effect of NELL1 and adipose-derived stem cells on promoting bone formation in osteogenesis imperfecta treatment.NELL1 与脂肪干细胞协同作用促进成骨不全症治疗中的骨形成。
Biomed Pharmacother. 2020 Aug;128:110235. doi: 10.1016/j.biopha.2020.110235. Epub 2020 May 23.
8
Gene therapy approaches for osteogenesis imperfecta.成骨不全症的基因治疗方法。
Gene Ther. 2004 Feb;11(4):408-16. doi: 10.1038/sj.gt.3302199.
9
Curative Cell and Gene Therapy for Osteogenesis Imperfecta.成骨不全症的治疗性细胞和基因治疗。
J Bone Miner Res. 2022 May;37(5):826-836. doi: 10.1002/jbmr.4549. Epub 2022 Apr 17.
10
Stem Cell Therapy as a Treatment for Osteogenesis Imperfecta.干细胞疗法治疗成骨不全症。
Curr Osteoporos Rep. 2020 Aug;18(4):337-343. doi: 10.1007/s11914-020-00594-3.
引用本文的文献
1
New Perspectives of Therapies in Osteogenesis Imperfecta-A Literature Review.成骨不全症治疗的新视角——文献综述
J Clin Med. 2024 Feb 13;13(4):1065. doi: 10.3390/jcm13041065.
2
Gene-repaired iPS cells as novel approach for patient with .基因修复的诱导多能干细胞作为治疗……患者的新方法。 （原文句子不完整）
Front Bioeng Biotechnol. 2023 Jun 30;11:1205122. doi: 10.3389/fbioe.2023.1205122. eCollection 2023.
3
Current Overview of Osteogenesis Imperfecta.成骨不全症概述。
Medicina (Kaunas). 2021 May 10;57(5):464. doi: 10.3390/medicina57050464.
4
The effect of adrenocorticotropic hormone on alpha-2-macroglobulin in osteoblasts derived from human mesenchymal stem cells.促肾上腺皮质激素对人骨髓间充质干细胞来源成骨细胞中α-2 巨球蛋白的影响。
J Cell Mol Med. 2020 Apr;24(8):4784-4790. doi: 10.1111/jcmm.15152. Epub 2020 Mar 12.
5
Enhancement of Mesenchymal Stem Cell-Driven Bone Regeneration by Resveratrol-Mediated SOX2 Regulation.白藜芦醇介导的SOX2调控增强间充质干细胞驱动的骨再生
Aging Dis. 2019 Aug 1;10(4):818-833. doi: 10.14336/AD.2018.0802. eCollection 2019 Aug.
6
Animal models of osteogenesis imperfecta: applications in clinical research.成骨不全症的动物模型：在临床研究中的应用
Orthop Res Rev. 2016 Sep 27;8:41-55. doi: 10.2147/ORR.S85198. eCollection 2016.
7
Comparison of Differentiation of Induced Pluripotent Stem Cells and Bone-Marrow Mesenchymal Stem Cells to Osteoblast: Osteogenesis versus Pluripotency.诱导多能干细胞与骨髓间充质干细胞向成骨细胞分化的比较：成骨作用与多能性
Int J Organ Transplant Med. 2016;7(2):91-96. Epub 2016 May 1.
8
Distribution pattern following systemic mesenchymal stem cell injection depends on the age of the recipient and neuronal health.全身注射间充质干细胞后的分布模式取决于受体的年龄和神经元健康状况。
Stem Cell Res Ther. 2017 Apr 18;8(1):85. doi: 10.1186/s13287-017-0533-2.
9
Lower Oncogenic Potential of Human Mesenchymal Stem Cells Derived from Cord Blood Compared to Induced Pluripotent Stem Cells.与诱导多能干细胞相比，脐带血来源的人间充质干细胞的致癌潜力更低。
Int J Organ Transplant Med. 2015;6(3):99-104.
10
Effect of Intra-Medullar and Intra-Venous Infusions of Mesenchymal Stem Cells on Cell Engraftment by Cell Tracking and Osteoinductivity in Rabbit Long Bones: A Pilot Study.骨髓内和静脉内输注间充质干细胞对兔长骨细胞植入的细胞追踪及骨诱导性影响：一项初步研究
Orthop Muscular Syst. 2014 Nov;3(3). doi: 10.4172/2161-0533.1000172.
本文引用的文献
1
Mesenchymal stem cells and cardiac repair.间充质干细胞与心脏修复
J Cell Mol Med. 2008 Oct;12(5B):1795-810. doi: 10.1111/j.1582-4934.2008.00457.x. Epub 2008 Aug 5.
2
Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors.成骨不全症（OI）的Brtl小鼠模型中骨量减少的细胞机制：成骨细胞功能降低与破骨细胞及其前体细胞增加之间的失衡。
J Bone Miner Res. 2008 Dec;23(12):1983-94. doi: 10.1359/jbmr.080804.
3
Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles.骨骼肌干细胞在营养不良性肌肉中高效、功能性植入。
Cell. 2008 Jul 11;134(1):37-47. doi: 10.1016/j.cell.2008.05.049.
4
CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta.隐性成骨不全症中的CRTAP和LEPRE1突变
Hum Mutat. 2008 Dec;29(12):1435-42. doi: 10.1002/humu.20799.
5
Comparative osteogenic transcription profiling of various fetal and adult mesenchymal stem cell sources.不同胎儿和成人间充质干细胞来源的成骨转录谱比较
Differentiation. 2008 Nov;76(9):946-57. doi: 10.1111/j.1432-0436.2008.00279.x. Epub 2008 Jun 13.
6
Immunosuppression by mesenchymal stromal cells: from culture to clinic.间充质基质细胞介导的免疫抑制：从培养到临床
Exp Hematol. 2008 Jun;36(6):733-41. doi: 10.1016/j.exphem.2008.03.006.
7
Distribution of murine adipose-derived mesenchymal stem cells in vivo following transplantation in developing mice.小鼠脂肪来源间充质干细胞在发育中小鼠体内移植后的分布
Stem Cells Dev. 2008 Apr;17(2):303-14. doi: 10.1089/scd.2007.0086.
8
Interspecies nuclear transfer: implications for embryonic stem cell biology.种间核移植：对胚胎干细胞生物学的影响。
Cell Stem Cell. 2007 Nov;1(5):502-12. doi: 10.1016/j.stem.2007.10.009.
9
Osteogenesis imperfecta.成骨不全症
Best Pract Res Clin Rheumatol. 2008 Mar;22(1):85-100. doi: 10.1016/j.berh.2007.12.012.
10
Transplantation of human fetal mesenchymal stem cells improves glomerulopathy in a collagen type I alpha 2-deficient mouse.人胎儿间充质干细胞移植可改善I型胶原蛋白α2缺陷小鼠的肾小球病变。
J Pathol. 2008 Apr;214(5):627-36. doi: 10.1002/path.2325.
Zotero 插件